NCT02343601

Brief Summary

The purpose of this study is to determine whether hemodynamic optimization with photoplethysmography (ClearSight, Edwards Lifesciences, Irvine, CA) during colorectal surgery could decrease the incidence of perioperative complications.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Dec 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 13, 2014

Completed
6 months until next milestone

Study Start

First participant enrolled

December 1, 2014

Completed
2 months until next milestone

First Posted

Study publicly available on registry

January 22, 2015

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

April 2, 2026

Status Verified

May 1, 2019

Enrollment Period

1.8 years

First QC Date

June 13, 2014

Last Update Submit

March 30, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Incidence of patients presenting at least one complication after colorectal surgery

    Two independent experts defined the presence of complication using an a priori classification.

    Up to 28 days after surgery (length of hospital stay)

Secondary Outcomes (3)

  • All complications happening after colorectal surgery

    Up to 28 days after surgery (length of hospital stay)

  • Real length of hospital stay

    Up to 28 days after surgery (length of hospital stay)

  • Perioperative mortality

    28 days after surgery

Other Outcomes (1)

  • Medico economic evaluation of cost of treatment

    Up to 28 days after surgery (length of hospital stay)

Study Arms (2)

Control group

NO INTERVENTION

Control group using a hemodynamic standard protocol

Photoplethysmography group

OTHER

Hemodynamic optimization using Photoplethysmography device (ClearSight, Edwards Lifesciences, Irvine, CA)

Device: Photoplethysmography

Interventions

Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period

Photoplethysmography group

Eligibility Criteria

Age18 Years - 95 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age\> 18 years
  • Colorectal surgery

You may not qualify if:

  • Pregnant women
  • Black skin
  • Chronic renal insufficiency (MDRD \<30 ml/min)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Caen University Hospital

Caen, 14 000, France

Location

Related Publications (1)

  • Fischer MO, Fiant AL, Boutros M, Flais F, Filipov T, Debroczi S, Pasqualini L, Rhanem T, Gerard JL, Guittet L, Hanouz JL, Alves A, Parienti JJ; PANEX3 study group. Perioperative hemodynamic optimization using the photoplethysmography in colorectal surgery (the PANEX3 trial): study protocol for a randomized controlled trial. Trials. 2016 Mar 22;17:159. doi: 10.1186/s13063-016-1278-4.

MeSH Terms

Conditions

Colorectal NeoplasmsCrohn Disease

Interventions

Photoplethysmography

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesInflammatory Bowel DiseasesGastroenteritis

Intervention Hierarchy (Ancestors)

PlethysmographyDiagnostic Techniques, CardiovascularDiagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Anne-Lise Fiant, MD

    University Hospital of Caen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 13, 2014

First Posted

January 22, 2015

Study Start

December 1, 2014

Primary Completion

October 1, 2016

Study Completion

December 1, 2016

Last Updated

April 2, 2026

Record last verified: 2019-05

Locations